Kodiak Sciences Inc. (KOD) · Aug 13, 2026 · Earnings

The quarter missed, but Kodiak’s real test still arrives in September

Miss — EPS loss $1.05 vs published consensus around $0.96–$0.97

EPS came in below published estimates as cash fell, but Kodiak preserved its September and December Phase 3 readout schedule.

The quarter missed the available earnings bar. Kodiak reported a $1.05 per-share loss versus published estimates clustered around roughly $0.96–$0.97, making the result modestly worse than expected.

MetricQ2 2026Q2 2025 / reference
Net loss$65.6 million$54.3 million (Net loss)
Loss per share$1.05$1.03 (Condensed Statements of Operations)
R&D expense$56.1 million$42.8 million (R&D Expenses)
G&A expense$10.8 million$12.8 million (G&A Expenses)
Cash and equivalents$125.9 million$209.9 million at Dec. 31, 2025 (Balance Sheet Data)

The higher loss reflects spending behind the pipeline, not a new commercial setback. R&D rose about 31% year over year as PEAK/PINNACLE clinical work and Phase 3 manufacturing accelerated, while G&A declined. That is understandable for a pre-commercial biotech, but it still means the company is consuming cash faster while revenue remains absent. (R&D Expenses; Condensed Statements of Operations)

The meaningful operating update was broadly on schedule rather than ahead of it. Kodiak completed enrollment in the first 300-patient PEAK cohort, began enrolling the roughly 910-patient ALTO study, and maintained September 2026 DAYBREAK data and December 2026 PEAK data timing. Those are constructive execution markers, but the readout calendar was already the central near-term expectation; the filing mostly confirms it rather than creating a fresh surprise. (Recent Business Highlights)

Net read: an earnings miss with the clinical setup intact. The $125.9 million cash balance is stated to support planned operations into 2027, but the filing does not add financing or extend that runway beyond the prior framing. With the next value-defining event still the September DAYBREAK topline readout, the financial result lands slightly below expectations while the clinical narrative remains broadly in line. (Cash Position; Phase 3 DAYBREAK Study)

What to watch next

DAYBREAK topline results, September 2026

Original filing on SEC EDGAR

More Kodiak Sciences Inc. news

The quarter missed, but Kodiak’s real test still arrives in September | KOD Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.